Third, in exerting a synergistic effect with multikinase inhibitors: lenvatinib blocks the VEGF pathway to inhibit tumor angiogenesis and reduce myeloid-derived suppressor cell (MDSC) infiltration, enhancing tislelizumab’s immune activation to form an “anti-angiogenesis-immune activation” synergy (23). Here, VEGFA is linked to neoplasm.